Search Results - "Raal, Frederick J"

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia by Raal, Frederick J, Kallend, David, Ray, Kausik K, Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J, Curcio, Danielle, Jaros, Mark J, Leiter, Lawrence A, Kastelein, John J.P

“…This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with…”
Get full text

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia by Stein, Evan A, Honarpour, Narimon, Wasserman, Scott M, Xu, Feng, Scott, Rob, Raal, Frederick J

“…BACKGROUND—Homozygous familial hypercholesterolemia is a rare, serious disorder with a substantial reduction in low-density lipoprotein (LDL) receptor…”
Get full text

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by Borén, Jan, Chapman, M John, Krauss, Ronald M, Packard, Chris J, Bentzon, Jacob F, Binder, Christoph J, Daemen, Mat J, Demer, Linda L, Hegele, Robert A, Nicholls, Stephen J, Nordestgaard, Børge G, Watts, Gerald F, Bruckert, Eric, Fazio, Sergio, Ference, Brian A, Graham, Ian, Horton, Jay D, Landmesser, Ulf, Laufs, Ulrich, Masana, Luis, Pasterkamp, Gerard, Raal, Frederick J, Ray, Kausik K, Schunkert, Heribert, Taskinen, Marja-Riitta, van de Sluis, Bart, Wiklund, Olov, Tokgozoglu, Lale, Catapano, Alberico L, Ginsberg, Henry N

“…Abstract…”
Get full text

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events by Sabatine, Marc S, Giugliano, Robert P, Wiviott, Stephen D, Raal, Frederick J, Blom, Dirk J, Robinson, Jennifer, Ballantyne, Christie M, Somaratne, Ransi, Legg, Jason, Wasserman, Scott M, Scott, Robert, Koren, Michael J, Stein, Evan A

“…In two randomized trials, evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), reduced LDL cholesterol levels…”
Get full text

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial by Raal, Frederick J, Prof, Honarpour, Narimon, MD, Blom, Dirk J, MD, Hovingh, G Kees, MD, Xu, Feng, MS, Scott, Rob, MD, Wasserman, Scott M, MD, Stein, Evan A, Prof

“…Summary Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused by very low or absent plasma clearance of LDL, substantially…”
Get full text

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events by Robinson, Jennifer G, Farnier, Michel, Krempf, Michel, Bergeron, Jean, Luc, Gérald, Averna, Maurizio, Stroes, Erik S, Langslet, Gisle, Raal, Frederick J, El Shahawy, Mahfouz, Koren, Michael J, Lepor, Norman E, Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Kastelein, John J.P

“…In a randomized trial, alirocumab (a monoclonal antibody that inhibits PCSK9), as compared with placebo, reduced LDL cholesterol levels by an additional 62…”
Get full text

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials by Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark J, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Lawrence, David, Friedman, Andrew, Garcia Conde, Lorena, Wright, R Scott

“…Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran…”
Get full text

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (From the Phase 3 ODYSSEY Program) by Gaudet, Daniel, MD, PhD, Watts, Gerald F., DSc, MD, PhD, FRCP, FRACP, Robinson, Jennifer G., MD, Minini, Pascal, PhD, Sasiela, William J., PhD, Edelberg, Jay, MD, PhD, Louie, Michael J., MD, Raal, Frederick J., PhD

“…Abstract Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are…”
Get full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial by Raal, Frederick J, Prof, Stein, Evan A, Prof, Dufour, Robert, MD, Turner, Traci, MD, Civeira, Fernando, MD, Burgess, Lesley, Prof, Langslet, Gisle, MD, Scott, Russell, Prof, Olsson, Anders G, Prof, Sullivan, David, MD, Hovingh, G Kees, MD, Cariou, Bertrand, MD, Gouni-Berthold, Ioanna, MD, Somaratne, Ransi, MD, Bridges, Ian, MSc, Scott, Rob, MD, Wasserman, Scott M, MD, Gaudet, Daniel, Prof

“…Summary Background Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased plasma LDL cholesterol…”
Get full text

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract by Mach, François, Ray, Kausik K, Wiklund, Olov, Corsini, Alberto, Catapano, Alberico L, Bruckert, Eric, De Backer, Guy, Hegele, Robert A, Hovingh, G Kees, Jacobson, Terry A, Krauss, Ronald M, Laufs, Ulrich, Leiter, Lawrence A, März, Winfried, Nordestgaard, Børge G, Raal, Frederick J, Roden, Michael, Santos, Raul D, Stein, Evan A, Stroes, Erik S, Thompson, Paul D, Tokgözoğlu, Lale, Vladutiu, Georgirene D, Gencer, Baris, Stock, Jane K, Ginsberg, Henry N, Chapman, M John

“…Abstract Aims To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic…”
Get full text

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia by Watts, Gerald F., Gidding, Samuel S., Hegele, Robert A., Raal, Frederick J., Sturm, Amy C., Jones, Laney K., Sarkies, Mitchell N., Al-Rasadi, Khalid, Blom, Dirk J., Daccord, Magdalena, de Ferranti, Sarah D., Folco, Emanuela, Libby, Peter, Mata, Pedro, Nawawi, Hapizah M., Ramaswami, Uma, Ray, Kausik K., Stefanutti, Claudia, Yamashita, Shizuya, Pang, Jing, Thompson, Gilbert R., Santos, Raul D.

“…This contemporary, international, evidence-informed guidance aims to achieve the greatest good for the greatest number of people with familial…”
Get full text

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment by Vuorio, Alpo, Kovanen, Petri T., Raal, Frederick J.

“…Patients with hypercholesterolemia often have coronary microvascular dysfunction (CMD). Viral infections, such as the SARS-CoV-2 infection, may also result in…”
Get full text

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S] by Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

“…Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9…”
Get full text

Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies by Botha, Theunis C., Pilcher, Gillian J., Wolmarans, Karen, Blom, Dirk J., Raal, Frederick J.

“…Pregnancy in HoFH females is associated with further elevation of already markedly elevated low density lipoprotein cholesterol (LDL-C) levels, particularly if…”
Get full text

Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis by Blom, Dirk J., Raal, Frederick J., Santos, Raul D., Marais, A. David

“…Purpose of Review The goal of this review is to evaluate the role of inhibiting the synthesis of lipoproteins when there is no or little residual LDL-receptor…”
Get full text

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation by Watts, Gerald F, Gidding, Samuel, Wierzbicki, Anthony S, Toth, Peter P, Alonso, Rodrigo, Brown, W. Virgil, Bruckert, Eric, Defesche, Joep, Lin, Khoo Kah, Livingston, Michael, Mata, Pedro, Parhofer, Klaus G, Raal, Frederick J, Santos, Raul D, Sijbrands, Eric J.G, Simpson, William G, Sullivan, David R, Susekov, Andrey V, Tomlinson, Brian, Wiegman, Albert, Yamashita, Shizuya, Kastelein, John J.P

“…Abstract Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)…”
Get full text

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial by Raal, Frederick J, Prof, Santos, Raul D, MD, Blom, Dirk J, MD, Marais, A David, Prof, Charng, Min-Ji, MD, Cromwell, William C, MD, Lachmann, Robin H, MRCP, Gaudet, Daniel, MD, Tan, Ju L, MB BS, Chasan-Taber, Scott, PhD, Tribble, Diane L, PhD, Flaim, JoAnn D, PhD, Crooke, Stanley T, MD

“…Summary Background Homozygous familial hypercholesterolaemia is a rare genetic disorder in which both LDL-receptor alleles are defective, resulting in very…”
Get full text

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) by Raal, Frederick J., MB BCh, MMed, PhD, Giugliano, Robert P., MD, SM, Sabatine, Marc S., MD, MPH, Koren, Michael J., MD, Langslet, Gisle, MD, Bays, Harold, MD, Blom, Dirk, PhD, MD, Eriksson, Mats, MD, Dent, Ricardo, MD, Wasserman, Scott M., MD, Huang, Fannie, MS, Xue, Allen, PhD, Albizem, Moetaz, MD, Scott, Rob, MD, Stein, Evan A., MD, PhD

“…Objectives The purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp)(a) from a pooled analysis of 4 phase II trials…”
Get full text

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study by Raal, Frederick J, Prof, Hovingh, G Kees, PhD, Blom, Dirk, MD, Santos, Raul D, Prof, Harada-Shiba, Mariko, Prof, Bruckert, Eric, Prof, Couture, Patrick, MD, Soran, Handrean, Prof, Watts, Gerald F, Prof, Kurtz, Christopher, MD, Honarpour, Narimon, MD, Tang, Lihua, PhD, Kasichayanula, Sree, PhD, Wasserman, Scott M, MD, Stein, Evan A, Prof

“…Summary Background Homozygous familial hypercholesterolaemia is a genetic disorder characterised by substantially raised LDL cholesterol, reduced LDL receptor…”
Get full text

Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study by Alsheikh-Ali, Alawi A, Omar, Mohamed I, Raal, Frederick J, Rashed, Wafa, Hamoui, Omar, Kane, Abdoul, Alami, Mohamed, Abreu, Paula, Mashhoud, Walid M

“…Increased urbanization in the developing world parallels a rising burden of chronic diseases. Developing countries account for ∼ 80% of global cardiovascular…”
Get full text